S3-E46.5 – Discussing NITs and Final Thoughts on NAFLD Summit

S3-E46.5 - Discussing NITs and Final Thoughts on NAFLD Summit
Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this final conversation, the group discusses NITs and what will change between now and when this conference convenes next year.

The 2022 NAFLD Summit presented a range of perspectives and insights on fatty liver and metabolic diseases. Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on site from Dublin to review their reactions immediately after the conference ended.

Discussing NITs and Final Thoughts on NAFLD Summit

This final conversation begins with Roger calling attention to a debate around NITs that took place on the opening day of the meeting. Mazen revisits what he has described on this podcast as the coming “combo-combo” world. The group generally agrees that biomarkers in primary care ought to be simple, cost effective and accessible. However, Sven utters a word of caution: while acknowledging the positive potential of NITs, it is still important to evaluate its limitations.

The episode concludes with a round of final reflections. Roger asks for panelists to forecast the most important thing that will have changed between now and when we return for the NAFLD Summit 2023. Surf on to find out what the panel predicts.

This episode is sponsored by Resoundant, a Mayo Clinic company and the developers of Magnetic Resonance Elastography. MRE is widely available with over 2000 locations worldwide, and can be done as a low-cost, rapid exam in just 5 minutes. Together with PDFF, this quantitative exam is called an Hepatogram – a powerful non-invasive alternative to liver biopsy in many cases. For more information, visit www.resoundant.com on the web.